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Abstract
Background
Cystinuria is an autosomal recessive disorder of dibasic amino acid transport in
the kidney and the intestine leading to increased urinary cystine excretion and
nephrolithiasis. Two genes, SLC3A1 and SLC7A9, coding respectively for rBAT
and b0,+AT, account for the genetic basis of cystinuria.
Methods
This study reports the clinical and molecular characterization of a French
cohort including 112 cystinuria patients and 25 relatives from 99 families.
Molecular screening was performed using sequencing and Quantitative Multi-
plex PCR of Short Fluorescent Fragments analyses. Functional minigene-based
assays have been used to characterize splicing variants.
Results
Eighty-eight pathogenic nucleotide changes were identified in SLC3A1 (63) and
SLC7A9 (25) genes, of which 42 were novel. Interestingly, 17% (15/88) and
11% (10/88) of the total number of variants correspond, respectively, to large-
scale rearrangements and splicing mutations. Functional minigene-based assays
were performed for six variants located outside the most conserved sequences
of the splice sites; three variants affect splice sites, while three others modify
exonic splicing regulatory elements (ESR), in good agreement with a new in
silico prediction based on DtESRseq values.
Conclusion
This report expands the spectrum of SLC3A1 and SLC7A9 variants and sup-
ports that digenic inheritance is unlikely. Furthermore, it highlights the rele-
vance of assessing large-scale rearrangements and splicing mutations to fully
characterize cystinuria patients at the molecular level.
ª 2017 Rouen University Hospital. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Introduction
Cystinuria (OMIM #220100) is an inherited autosomal
recessive aminoaciduria due to pathogenic variants in the
SLC3A1 (solute carrier family 3 member 1 OMIM
#104614) or SLC7A9 (solute carrier family 7 member 9
OMIM # 604144) genes, encoding respectively for rBAT
and b0, +AT. These proteins are subunits of a dibasic
amino acid transporter, named B0. This transporter is
expressed as a stable tetramer (Reig et al. 2002) in the renal
proximal tubule and the intestinal mucosa (Palacin et al.
2005). Tubular transport deficiency induces an abundant
urinary excretion of dibasic amino acids, cystine, ornithine,
arginine, and lysine. Cystine is poorly soluble and its crys-
tallization results in calculi. Thus, nephrolithiasis is the
only clinical expression of cystinuria. The global incidence
of cystinuria is estimated at 1 per 7,000 births and varies
according to geographical location (Chillaron et al. 2010).
Cystinuria is characterized by a high rate of nephrolithiasis
recurrence, which exceeds 90% in the absence of medical
management and is up to 60% in treated patients. Ade-
quate medical management aims i) to remove calculi and
ii) to prevent cystine crystallization by increasing urine pH
which preserves renal function (Prezioso et al. 2015).
Dello Strologo et al. (Dello Strologo et al. 2002) pro-
posed a molecular classification based on the identifica-
tion of pathogenic variants in the SLC3A1 and SLC7A9
genes. According to this classification, type A cystinuria is
caused by biallelic variations that affect the SLC3A1 gene
(genotype AA), type A heterozygote individuals have nor-
mal urinary amino acid excretion; type B cystinuria is
due to pathogenic variants in both SLC7A9 alleles (geno-
type BB), type B heterozygote individuals may have nor-
mal or enhanced urinary excretion of dibasic amino acid;
type AB (genotype AB) has been proposed with a possible
digenic inheritance (Dello Strologo et al. 2002). However,
recent reports demonstrated that patients with an AB
genotype have a third variant leading to genotype AAB or
ABB (Font-Llitjos et al. 2005; Chillaron et al. 2010). One
hundred fifty-one and 103 variants are reported in
SLC3A1 and SLC7A9 genes, respectively, in the public
Human Genome Mutation Database accessed on October
2016 (Stenson et al. 2012). Some pathogenic variants are
commonly found such as c.808C>T - p.Arg270*(Pras
et al. 1995), c.1400T>C - p.Met467Thr (Calonge et al.
1994), c.647C>T - p.Thr216Met in SLC3A1 gene, and
c.313G>A - p.Gly105Arg and c.1445C>T - p.Pro482Leu in
SLC7A9 gene (Chillaron et al. 2010).
Of note, large-scale rearrangements (deletions and
duplications) represent a significant proportion of
SLC3A1 and SLC7A9 mutated alleles in cystinuria patients
ranging from 11% (Bisceglia et al. 2010) to 33% (Barbosa
et al. 2011). The genomic deletions of SLC3A1 region
may involve neighboring genes (PREPL, CAMKMT (pre-
vious name C2orf34), and PPMB1).
Patients with hypotonia-cystinuria syndrome present
with cystinuria, neonatal seizures, developmental delay
and dysmorphic features and molecular studies allow the
identification of homozygous large deletion of SLC3A1
locus (Martens et al. 2007).
A prenatal presentation has been characterized with an
ultrasound exam showing a hyperechogenicity of the
colon secondary to cystine crystal deposition (Brasseur-
Daudruy et al. 2006). This finding may be related to the
increase in cystine concentration in the amniotic fluid
which is subsequently swallowed by the fetus.
SLC3A1 and SLC7A9 variants responsible for splicing
alterations have been previously reported as pathogenic
mutations. Indeed, among the 254 SLC3A1 and SLC7A9
variants listed in public Human Gene Mutation Database
(HGMD, 2017), 23 are considered as splicing mutations.
The large majority of them are located in the most con-
served intronic sequences of the 50 or 30 splice sites, that
is, 2, 1/+1, +2 and are today systematically classified
as pathogenic mutations. So far, if these specific dinu-
cleotides are excluded, very few intronic or exonic
SLC3A1 and SLC7A9 variants have been experimentally
shown to induce an alteration of 50 or 30 splice sites (Pras
et al. 1998; Font-Llitjos et al. 2005; Barbosa et al. 2011)
or to be responsible for a modification of exonic splicing
regulatory elements (ESR) (Kummer et al. 2014).
Molecular studies of cystinuria have been reported in
patients from many countries in Europe except France. In
this study, we aimed to characterize at clinical and molec-
ular levels, a French cohort of patients with cystinuria.
We hypothesized that large-scale rearrangements and
splicing variants may account for a significant number of
pathogenic variants. Thus, Quantitative Multiplex PCR of
Short Fluorescent Fragments (QMPSF) analyses and func-
tional minigene-based assays have been used to character-
ize these specific variants.
Material and Methods
Recruitment of patients
A total of 112 patients and 25 relatives from 99 families
with cystinuria were investigated.
Clinical data were recorded through a questionnaire
sent to adult and pediatric nephrology and urology
departments. The questionnaire addressed age at first
symptoms, stone recurrence rates, metabolic evaluations,
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medical therapy, and follow-up. Written informed con-
sents were obtained either from the adult patients or from
the parents when the patient was under 18 years old. All
patients included in this study were seen at the outpatient
clinic by a clinical geneticist and/or a nephrologist.
Clinical and biochemical diagnoses
Clinical diagnosis was confirmed by quantitation of uri-
nary amino acid and calculi identification when possible.
Nomenclature
Nucleotide numbering is based on the cDNA sequence of
SLC3A1 (NM_000341.3) and SLC7A9 (NM_014270.4),
with c.1 denoting the first nucleotide of the translation
initiation codon, as recommended by the Human Gen-
ome Variation Society.
Molecular characterization
Probands and their relatives were analyzed for variants in
SCL3A1 and SLC7A9 genes. Variant screening was per-
formed by Sanger sequencing. Quantitative Multiplex
PCR of Short Fluorescent Fragments analysis (QMPSF)
was implemented for the detection of large-scale rear-
rangements.
DNA extraction and sequencing analyses
Genomic DNA was extracted from venous blood using
QIAamp DNA Blood Mini Kit Qiagen and was ampli-
fied in vitro by PCR. Multiple pairs of primers were syn-
thesized to amplify each of SLC3A1 and SLC7A9 exonic
regions, including intron/exon boundaries and promoter
(primers sequences are available upon request).
PCR reactions were carried out in 1X Thermo Scientific
Buffer IV, 1.5 mM MgCl2, 100 lM dNTPs, 0.025 U/lL taq
polymerase (Thermo Scientific), 0.6 lM of each primer.
Touchdown PCR consisted of one cycle of 95°C for 5 min
for the initial denaturation step followed by 12 cycles of
denaturation at 95°C for 25 sec, varying annealing (60-48°)
for 25 sec, and extension at 72°C. Then, 35 cycles were per-
formed as follows: denaturation at 95° for 25 sec, annealing
at 48° for 25 sec and extension at 72°C for 25 sec. PCR was
terminated after a final cycle at 72°C for 5 min.
Direct PCR product sequencing of SLC3A1 and
SLC7A9 genes, was performed with an ABI prism Bigdye
Terminator cycle Sequencing Ready Reaction Kit (PE
Applied Biosystem/and ABI model 3130xl Genetic Analy-
ser). Patients’ genomic sequences comparison with the
reference sequence was done by Variant Reporter software
(Applied Biosystem).
QMPSF analyses
Short exonic fragments were simultaneously amplified by
PCR and distributed across seven multiplex reactions for
SLC7A9, PPM1B, SLC3A1, PREPL, and CAMKMT genes
(primer sequences are available upon request); 38 ampli-
cons with a size between 140 and 306 bp were designed to
cover these gene sequences. One additional autosomic frag-
ment, corresponding to the exon 13 of the HMBS gene
located on chromosome 11, was coamplified, as a control
PCR. A fragment from chromosome X was coamplified as
quantification control (exon 8 of the NHS gene or exon 4
of the MECP2 gene). The PCR reaction was performed in a
25 lL final volume containing 100 ng of genomic DNA,
0.3–0.9 mM of each primer, 200 mM dNTPs, 25 mM
MgCl2, 10% DMSO, 1X Thermo Scientific Buffer IV, and
1U of Taq DNA polymerase (ABgene, Courtaboeuf,
France). The PCR consisted of 25 cycles of 94°C for 15 sec,
50°C for 15 sec, and 72°C for 15 sec, preceded by a 5-min
initial denaturation step at 94°C and followed by a 5-min
final extension at 72°C. One lL of the PCR product was
resuspended in a mix containing 10 lL of deionized for-
mamide, 0.5 lL of GeneScan-500 Rox (PE Applied Biosys-
tems, Foster City, CA, USA). After denaturation for 2 min
30 sec at 94°C, 2 lL of each sample was loaded on an
Applied Biosystems model 3130xl Genetic Analyzer auto-
mated sequencer (PE Applied Biosystems). Data were ana-
lyzed using the Genescan software (PE Applied
Biosystems,). Electropherograms were superimposed to
those generated from a normal control DNA by adjusting
the peaks obtained for the control amplicon and the heights
of the corresponding peaks to the same level. Peaks were
then compared between the different samples.
In silico analysis of the variants
Allele frequency analysis
The frequency in human population of the novel single-
nucleotide variants identified in this study was evaluated
using different databases (Exome Aggregation Consortium
(Lek et al. 2016), Exome Sequencing Project (ESP) (Auer
et al. 2016), the 1000 Genomes Project (Auton et al. 2015),
and the dbSNP (Kitts et al. 2013). Only the variants with
frequency below 1% were considered for further analyses.
Computational predictions for the functional
impact of missense variants
The potential functional impact on the protein of novel
missense variants with low frequency were then evaluated
using in silico methods, such as Align GVGD (Tavtigian
et al. 2008) SIFT (Kumar et al. 2009), PolyPhen2
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(Adzhubei et al. 2010), and MutationTaster (Schwarz
et al. 2010).
Bioinformatics predictions of splicing variants
The in silico tool MaxEntScan (Yeo and Burge 2004) was
used to predict variant-induced alterations of 30 and 50
splice sites. This algorithm was interrogated using the
integrated software Alamut (Interactive Biosoftware,
France). One newly developed bioinformatics approach
was used to evaluate the potential impact of variants on
exonic splicing regulatory elements (ESR). This method is
based on the reported quantitative evaluation of all RNA
hexamers as potential ESR (Ke et al. 2011), which allows
the calculation of total ESRseq score changes (DtESRseq)
for each variant, as previously described (Di Giacomo
et al. 2013; Soukarieh et al. 2016).
Functional splicing minigene reporter assay
In order to assess the impact on splicing of SLC3A1 and
SLC7A9 variants, functional minigene-based assays were
performed, as previously described (Tournier et al. 2008;
Gaildrat et al. 2010) (Fig. 1A). Briefly, the SLC3A1 or
SLC7A9 exons relevant to this study along with approxi-
matively 150 bp of flanking intronic sequences were
amplified by PCR from patient genomic DNA using for-
ward and reverse primers carrying 50 tails that contained
BamHI and MluI restriction sites, respectively (primer










































Figure 1. Effect on splicing of selected variants located in SLC3A1 and SLC7A9 genes, assessed using a functional minigene assay. (A) Schematic
representation of the pCAS2-SLC3A1/SLC7A9 minigene used in the splicing reporter assay. Boxes indicate exons, whereas lines in between
represent introns. The minigenes were generated by inserting a genomic fragment, containing the SLC3A1 or SLC7A9 exon of interest (gray box),
as well as part of the upstream and downstream flanking intronic sequences (thick lines), into the intron of the minigene using the BamHI and
MluI restriction sites. Expression of the minigenes is driven by the CMV promoter. Arrows above the minigene exons A and B (white boxes)
indicate the positions of primers used in RT-PCR analysis. (B–F) Analysis of the splicing pattern of the wild-type and mutant pCAS2-SLC3A1/
SLC7A9 minigenes for the selected variants. Wild-type (WT) and mutant pCAS-2 SLC3A1/SLC7A9 constructs were transiently expressed in HeLa
cells by transfection. The splicing patterns of the minigene transcripts were then analyzed by RT-PCR as described under Materials and Methods.
The image shows the electrophoresis on a 2% agarose ethidium bromide-stained gel of the RT-PCR products obtained for each minigene. The
identities of the RT-PCR products, with the inclusion (+) or the skipping (D) of the exon are indicated on the right.
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with BamHI and MluI restriction enzymes, the PCR
products were inserted into the intron of the splicing
reporter minigene vector pCAS2 (Fig. 1A). This vector
carries two exons (named A and B) with a sequence
derived from the human SERPING1/C1NH gene, sepa-
rated by an intron with BamHI and MluI cloning sites
(Tournier et al. 2008; Gaildrat et al. 2010; Soukarieh et al.
2016). Expression of the pCAS2 minigene is under the
control of a CMV promoter. The inserts of all minigene
constructs were sequenced to verify the presence of the
variants and to ensure that no extra mutations were
introduced during the cloning process.
HeLa cells were obtained from ATCC and grown in Dul-
becco’s modified Eagle’s medium (Life Technologies), sup-
plemented with 10% fetal calf serum, under a 5% CO2
atmosphere at 37°C. Next, WT and mutant pCAS2 mini-
gene plasmids were transiently transfected into HeLa cells
using the FuGENE 6 transfection reagent (Roche Applied
Science). Total RNA was then extracted 24 h posttransfec-
tion using the NucleoSpin RNA II kit (Macherey Nagel),
according to the manufacturer’s instructions, including a
DNase I treatment. The splicing pattern of each minigene
was analyzed by RT-PCR (30 cycles of amplification) from
200 ng total RNA in a 25 lL reaction volume, using the
OneStep RT-PCR kit (Qiagen), with the primers pCAS-
KO1F (50-TGACGTCGCCGCCCATCAC-30) and pCAS2R
(50-ATTGGTTGTTGAGTTGGTTGTC-30), respectively,
located in exons A and B of the minigene pCAS2 (Fig. 1A).
RT-PCR products were separated by electrophoresis on 2%
agarose gels containing ethidium bromide and visualized
by exposure to ultraviolet light under nonsaturating condi-
tions using the Gel Doc XR image acquisition system (Bio-
RAD). Gel extraction and sequencing of the RT-PCR
products were carried out as previously described [Gaildrat
et al. 2010].
Statistical analysis
As a first step, we conducted a descriptive analysis of the
population with the means and medians for quantitative
variables and frequencies for qualitative variables. In a
second step, a univariate analysis was performed to deter-
mine what might be the factors influencing genotype–
phenotype correlation. For this, we used the Wilcoxon
test, test of comparison of two observed medians. In a
third step, we compared our results, with those of three
recent European studies on genotype distribution
(Chatzikyriakidou et al. 2008; Bisceglia et al. 2010; Wong
et al. 2015) and with those of a meta-analysis on recur-
rent variant frequency (Chillaron et al. 2010). A Person’s
Chi-squared test was performed to compare two observed
frequencies or Fisher’s exact test if the sample sizes
required.
An alpha risk of 5% and a significant level of P < 0.05
were defined for each statistical test.
All statistical analyses were performed using Excel 2007
and the R statistical software.
Results
Identification of 42 novel pathogenic
variants in SLC3A1 and SLC7A9 genes
This study reports the clinical and molecular characteriza-
tion of a French cohort including 112 cystinuria patients
and 25 relatives from 99 families. We identified 115 vari-
ants in SLC3A1 (69) and SLC7A9 (46) genes. A variant
was considered as not pathogenic if it exhibits an allele
frequency above 1% in human population. Based on this
criterion, 24 variants were considered as benign
(Table S1). Besides, in our cohort, the variant SLC3A1
c.231T>A – p.(=) has always been identified in combina-
tion with the pathogenic variant SLC3A1 c.1400T>C -
p.Met467Thr in 25 patients. The complete linkage of
these two variants has been previously described in other
populations (Gasparini et al. 1995; Harnevik et al. 2001).
The remaining 90 variants included 8 nonsenses, 14
small deletions/insertions, 15 large-scale rearrangements, 4
intronic variants located in the most conserved sequences
of splice sites (-2,-1/+1,+2), 44 missenses, and 5 variants
of unknown significance (VUS) (three synonymous and
two intronic variants outside the most conserved
sequences of splice sites).
Among these variants, 46 were previously reported
(Tables 1 and 2). The remaining 44 novel variants
included six nonsenses, nine small deletions/insertions,
eight large-scale rearrangements, two intronic variants
located in the most conserved sequences of splice sites
(2,1/+1,+2), 17 missenses, and two variants of
unknown significance (VUS): 1 synonymous and 1 intro-
nic variant outside the most conserved sequences of splice
sites. Except for the missense variants and VUS, these
variants were considered as pathogenic without any fur-
ther analysis. For the missense variants, 15 were assumed
to be deleterious based on the output of at least two of
the following in silico algorithms, Align GVGD (Tavtigian
et al. 2008), SIFT (Kumar et al. 2009), PolyPhen2
(Adzhubei et al. 2010), or MutationTaster (Schwarz et al.
2010) (Table S2). Hence, two missense variants in
SLC7A9, c.26G>A (p.Arg9Gln) and c.397T>C (p.Ser133-
Pro), were classified as variants of unknown significance
because they were predicted nonpathogenic by all or by
three out of four algorithms, respectively. For the synony-
mous and intronic variants located outside the most con-
served sequences of splice sites, their functional impacts
on splicing were assessed using splicing minigene assays.
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Table 1. SLC3A1 sequence variants.
Variant type Position Nucleotide change Predicted protein Alleles Patients Reference
Missense Exon 1 c.257G>A p.(Arg86Gln) 1 1 Novel
Exon 1 c.371A>G p.(Tyr124Cys) 1 1 Font-Llitjos et al. (2005)
Exon 2 c.503C>T p.(Ser168Leu) 1 1 Novel
Exon 2 c.535G>T p.(Asp179Tyr) 2 2 Skopkova, et al., (2005)
Exon 2 c.566C>T p.(Thr189Met) 2 2 Font-Llitjos et al. (2005)
Exon 2 c.595G>C p.(Ala199Pro) 1 1 Novel
Exon 3 c.647C>T p.(Thr216Met) 16 10 Bisceglia et al. (2010)
Exon 3 c.647C>G p.(Thr216Agr) 1 1 Novel
Exon 3 c.763T>G p.(Trp255Gly) 2 2 Novel
Exon 4 c.789T>G p.(Ser263Arg) 1 1 Novel
Exon 4 c.851A>G p.(Asp284Gly) 1 1 Novel
Exon 6 c.1051A>G p.(Thr351Ala) 1 1 Novel
Exon 6 c.1094G>T p.(Arg365Leu) 1 1 Albers, et al., (1999)
Exon 7 c.1144G>T p.(Gly382Trp) 1 1 Novel
Exon 7 c.1190A>G p.(Tyr397Cys) 3 2 Eggermann, (2009)
Exon 7 c.1318T>C p.(Trp440Arg) 2 1 Novel
Exon 8 c.1354C>T p.(Arg452Trp) 4 4 Endsley, et al., (1997)
Exon 8 c.1364C>T p.(Ser455Leu) 2 2 Font-Llitjos et al. (2005)
Exon 8 c.1367G>A p.(Arg456His) 2 1 Font-Llitjos et al. (2005)
Exon 8 c.1400T>C p.(Met467Thr) 27 25 Calonge et al. (1994)
Exon 8 c.1400T>A p.(Met467Lys) 2 2 Calonge et al. (1994)
Exon 9 c.1518G>C p.(Lys506Asn) 2 1 Novel
Exon 9 c.1527G>A p.(Met509Ile) 1 1 Novel
Exon 9 c.1529A>C p.(Gln510Pro) 1 1 Novel
Exon 9 c.1607T>G p.(Val536Gly) 2 2 Gitomer, et al., (1998)
Exon 10 c.1640C>G p.(Ser547Trp) 1 1 Bisceglia, et al., (2001)
Exon 10 c.1684G>C p.(Glu562Gln) 1 1 Brauers and Eggermann, (2006)
Exon 10 c.1701G>T p.(Arg567Ser) 1 1 Brauers and Eggermann, (2006)
Exon 10 c.1796T>C p.(Phe599Ser) 1 1 Harnevik et al. (2001)
Nonsense Exon 1 c.163C>T p.(Gln55*) 1 1 Novel
Exon 2 c.464T>G p.(Leu155*) 1 1 Novel
Exon 4 c.792G>A p.(Trp264* 2 2 Chatzikyriakidou et al. (2008)
Exon 4 c.808C>T p.(Arg270*) 7 5 Pras et al. (1995)
Exon 6 c.1134C>A p.(Tyr378*) 1 1 Novel
Exon 8 c.1352C>G p.(Ser451*) 1 1 Novel
Exon 9 c.1459G>T p.(Gly487*) 1 1 Novel
Exon 10 c.2011C>T p.(Arg671*) 1 1 Novel
Variant type Position Variant (nucleotide change) Predicted protein Alleles Patients Reference
Small deletion Exon 5 c.979_980del p.(Asp327*) 1 1 Horsford,
et al., (1996)
Exon 10 c.1693_1695del p.(Leu565del) 1 1 Novel
Exon 10 c.1699_1700del p.(Arg567Glyfs*9) 3 3 Font-Llitjos
et al. (2005)
Exon 10 c.1750del p.(Arg584Glufs*14) 1 1 Gasparini
et al. (1995)
Exon 10 c.1754_1755del p.(Glu585Alafs*24) 1 1 Novel
Small insertion Exon 2 c.594dup p.(Ala199Serfs*4) 1 1 Novel
Exon 9 c.1545_1563dup p.(Ala522Lysfs*6) 1 1 Novel
Exon 10 c.1744_1745insC p.(Tyr582Serfs*28) 1 1 Novel
Deletion-insertion Exon 7 c.1159_1160delinsAA p.(Ala387Lys) 2 2 Novel
Splicing Intron 1 c.430+1G>T1 p.(?)3 1 1 Novel
Exon 5 c.1011G>A2 p.(Pro337=)3 3 3 Saadi
et al. (1998)
(Continued)
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In addition, variants previously reported as splicing
mutations without functional data were included in this
analysis.
Splicing effect of selected SLC3A1 and
SLC7A9 variants
In this study, four SLC3A1 and SLC7A9 variants were
identified at the most conserved intronic positions (2,
-1/+1, +2) of the splice site sequences. (Tables 1 and
2). Two of them have been previously reported, that is,
SLC3A1 c.1500+1G>T (Saadi et al. 1998) and SLC7A9
c.604+2T>C (Font-Llitjos et al. 2005), whereas the two
others were novel, that is, SLC3A1 c.430+1G>T and
SLC7A9 c.1074+2T>C. All of them were considered as
splicing pathogenic mutations. We hypothesized that,
among the variants identified in this cohort, additional
variants could impact splicing. Initially, a potential
effect on splice sites was predicted, using the algorithm
MaxEntScan (Yeo and Burge 2004), for four variants
of unknown significance identified in this study
(Table 3). Indeed, SLC3A1 c.1011G>A (p.=), SLC3A1
c.1617+5G>A, and SLC7A9 c.1399+3_+6del were pre-
dicted to alter reference 50 splice sites, whereas SLC7A9
c.120G>A (p.=) could create a new 30 splice site. The
impact on RNA splicing of these selected variants was
then assessed using a functional minigene splicing assay
(Fig. 1A).
In this assay, our results showed that all the processed
RNA expressed from the wild-type SLC3A1 exon 5 mini-
gene retained SLC3A1 exon 5, whereas the major spliced
transcripts expressed from the mutant SLC3A1
c.1011G>A minigene exhibited the skipping of exon 5
(Fig. 1B). A second minor aberrant transcript, corre-
sponding to the inclusion of SLC3A1exon 5 deleted for
the last 21 bp, was also detected. These data are consis-
tent with the bioinformatics predictions assessing the
effect of SLC3A1 c.1011G>A on splicing, suggesting that
this synonymous variant, located at the last position of
exon 5, alters the strength of the reference 50 splice site
(Table 3). The minor effect is predicted to be the conse-
quence of the use of a cryptic exonic 50 splice site, located
21 nucleotides upstream the reference 50 splice site (data
not shown).
Table 1. Continued.
Variant type Position Variant (nucleotide change) Predicted protein Alleles Patients Reference
Intron 8 c.1500+1G>T1 p.(?)3 3 3 Horsford,
et al., (1996)
Intron 9 c.1617+5G>A2 p.(?)3 1 1 Novel
Duplication Exon 4 and 5 c.(765+1_766-1)_
(1011+1_1012-1)dup
p.(?) 1 1 Novel
Exon 5 to 9 c.(891+1_892-1)_
(1617+1_1618-1)dup
p.(?) 17 16 Schmidt
et al. (2003)




p.(?) 1 1 Novel
Exon 2 and exon 3 c.(430+1_431-1)_(765+1_766-1)del p.(Gly144Valfs*12) 1 1 Gitomer,
et al., (1998)
Exon 2 to exon 4 c.(430+1_431-1)_(891+1_892-1)del p.(Ile145Asnfs*11) 1 1 Bisceglia
et al. (2010)




p.(?) 4 3 Jaeken,
et al., (1996)
Exon 3 to exon 9 c.(610+1_611-1)_(1616+1_1617-1)del p.(Leu205Profs*22) 1 1 Novel
Exon 4 SLC3A1 to
exon 9
c.(765+1_766-1)_(1616+1_1617-1)del p.(Leu256_Pro337del) 1 1 Novel




p.(?) 2 1 Jaeken,
et al., (2006)




p.(?) 1 1 Novel
Exon 8 c.(1332+1_1333-1)_(1500+1_1501-1)del p.(Ile445_Ile500del) 1 1 Novel




p.(?) 1 1 Jaeken,
et al., (2006)




p.(?) 1 1 Novel
1Variants located in the canonical intronic splice site sequences.
2Variants with an impact on splicing in minigene assay (this study).
3Predicted consequence at the protein level without taking into account the impact of the variant on splicing.
379ª 2017 Rouen University Hospital. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
P. Gaildrat et al. Cystinuria: Characterization of a French Cohort
Table 2. SLC7A9 sequence variants.
Mutation type Position Variant (nucleotide change) Predicted protein Alleles Patients Reference
Missense Exon 3 c.131T>C p.(Ile44Thr) 1 1 Leclerc, et al., (2002)
Exon 4 c.313G>A P.(Gly105Arg) 14 11 Feliubadalo, et al., (1999)
Exon 4 c.368C>T p.(Thr123Met) 1 1 Font et al. (2001)
Exon 4 c.380T>C p.(Ile127Thr) 1 1 Novel
Exon 5 c.508G>A p.(Val170Met) 1 1 Feliubadalo, et al., (1999)
Exon 5 c.511C>G p.(Arg171Gly) 1 1 Novel
Exon 5 c.517G>C p.(Gly173Arg) 1 1 Lee, et al., (2010)
Exon 5 c.544G>A p.(Ala182Thr) 3 3 Feliubadalo, et al., (1999)
Exon 5 c.562G>A p.(Val188Met) 1 1 Font-Llitjos et al. (2005)
Exon 10 c.992C>T p.(Ala331Val) 2 2 Botzenhart, et al., (2002)
Exon 10 c.997C>T p.(Arg333Trp) 2 1 Font et al. (2001)
Exon 11 c.1166C>T p.(Thr389Met) 1 1 Wong et al. (2015)
Small deletion Exon 4 c.285del P.(Glu96Serfs*5) 1 1 Novel
Exon 4 c.414_415del p.(Pro139Leufs*69) 1 1 Wong et al. (2015)
Small insertion Exon 6 c.614dup p.(Asn206Glufs*3) 5 4 Leclerc, et al., (2002)
Exon 12 c.1393dup P.(Ile465Asnfs*23) 1 1 Novel
Deletion-Insertion Exon 3 c.91delinsTGTGAT p.(Gly31Cysfs*61) 1 1 Novel
Splicing Exon 3 c.120G>A2 p.(Val40=)3 1 1 Wong et al. (2015)
Exon 3 c.209C>T2 p.(Ala70Val)3 1 1 Font et al. 2001)
Intron 5 c.604+2T>C1 p.(?)3 1 1 Font-Llitjos et al. (2005)
Exon 10 c.1032C>T2 p.(Ile344=)3 1 1 Novel
Intron 10 c.1074+2T>C1 p.(?)3 1 1 Novel
Intron 12 c.1399+3_1399+6del2 p.(?)3 1 1 Font et al. (2001)
Large deletion Exon 10 c.(977+1_978-1)_(1074+1_1075-1)del p.(Leu327Valfs*3) 1 1 Novel
Exon 12 c.(1224+1_1225-1)_(1399+1_1400-1)del p.(Val409Serfs*10) 2 2 Font-Llitjos et al. (2005)
1Variants located in the canonical intronic splice site sequences.
2Variants with an impact on splicing in minigene assay (this study).
3Predicted consequences at the protein level without taking into account the impact of the variant on splicing.










on RNA and Protein
SLC3A1 c.1011G>A Last base of
exon 5
Reference 50 ss: 6.866 ? 0 n.a. Exon 5 skipping (major) r.892_1011del,
p.Glu_Pro337del
c.1617+5G>A +5 intron 9 Reference 50 ss: 9.1 ? 2.3 n.a. Exon 5 del 21 nt (minor) r.991_1011del,
p.Val331_Pro337del
Exon 9 skipping (full) r.1501_1617,
p.Asn501_Asp539del
SLC7A9 c.120G>A +33 exon 3 Creation 30 ss: 0 ? 6.6 2.9 Exon 3 skipping (major) r.88_235del,
p.Leu30Valfs*11
c.209C>T 27 exon 3 No change 1.8 Exon 3 skipping (major) r.88_235del,
p.Leu30Valfs*11
c.225C>T1 11 exon 3 No change 2.2 Exon 3 skipping1 r.88_235del,
p.Leu30Valfs*11




Reference 50 ss :
10.1 ? 0
n.a. Exon 12 skipping (full) r.1225_1399del,
p.Val409Serfs*10
Wt, wild-type; Var, variant; n.a., not applicable; ss, splice site; ESR, exonic splicing regulatory elements.
1Kummer et al. (2014).
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The second tested variant, SLC3A1 c.1617+5G>A,
located in intron 9, led to total skipping of exon 9 in the
minigene splicing assay (Fig. 1C). These data are consis-
tent with the bioinformatics predictions suggesting that
this variant modified the reference 50 splice site of intron
9 (Table 3).
The SLC7A9 c.1399+3_+6del variant, located in intron
12, was identified in patient P82, who also carries another
variant in trans, c.1393dup, in exon 12 (Table S3). Both
variants were tested in the minigene splicing assay. The
results showed that all the processed RNA expressed from
the wild-type and the mutant c.1393dup SLC7A9 exon 12
minigenes retained SLC7A9 exon 12, while the mutant
c.1399+3_+6del induced exon 12 skipping (Fig. 1D).
These results are in good agreement with the in silico data
which showed that this variant was responsible for the
destruction of the reference 50 splice site (Table 3).
The synonymous variant SLC7A9 c.120G>A - p.(=),
located in exon 3, was identified in patient P96, who also
carries in trans a missense variant in this exon, c.209C>T
- p.(Ala70Val) (Table S3). Both variants were then tested
in the minigene splicing assay. This study revealed that
the wild-type SLC7A9 exon 3 minigene generated two dif-
ferent transcripts: a major transcript corresponding to the
normal inclusion of exon 3 and a minor transcript lack-
ing this exon (Fig. 1E). In contrast, minigene constructs
carrying either the SLC7A9 c.120G>A or c.209C>T vari-
ants produced a major transcript without exon 3. These
data were surprising because the bioinformatics predic-
tions dedicated to splice site analysis suggested that the
variant c.120G>A would create a new 30 splice site
whereas no effect was predicted for the variant c.209C>T
(Table 3). The skipping of exon 3 induced by these two
variants might then be the consequence of an alteration
of exonic splicing regulatory elements (ESR). Interest-
ingly, the output of a new in silico method based on the
calculation of total ESRseq score changes (DtESRseq) (Ke
et al. 2011; Di Giacomo et al. 2013; Soukarieh et al.
2016) supports this hypothesis. Indeed, SLC7A9 c.120G>A
and c.209C>T are associated with negative DtESRseq val-
ues, -2.9 and -1.8, respectively (Table 3), which suggest
that these two variants induce the exon 3 skipping
through the destruction of exonic splicing enhancer (ESE)
and/or the creation of exonic splicing silencer (ESS).
In addition to these four variants initially selected
based on splice site predictions, we also tested the impact
on splicing of the variant SLC7A9 c.1032C>T p.(=) based
on its negative DtESRseq value (-2.6) (Table 3), which
suggested a potential impact on ESR. In the functional
minigene assay, the wild-type SLC7A9 exon 10 minigene
generated two different transcripts: a major one with exon
10 and a minor one without (Fig. 1F). The SLC7A9
c.1032C>T variant was responsible for the major
production of transcripts lacking exon 10, suggesting an
effect through the alteration of ESR.
For all these variants, the predicted consequences at the
RNA and protein levels of the splicing alteration were
evaluated (Table 3).
Large-scale rearrangements in SCL3A1 and
SLC7A9 genes
QMPSF analyses were conducted in 50 cases and allowed
the characterization of 11 deletions, 2 duplications in
SLC3A1 gene and 2 deletions in SCL7A9 gene, 8 of which
are novel (Fig. 2).
Large-scale rearrangement mapping allowed us to
restore an accurate genotype in several families. Hence,
QMPSF analyses were performed in patients in whom an
AB genotype or a single variant has been identified after
sequencing analyses. The identification of these rearrange-
ments enabled us to discard an AB genotype being
enough to explain full-blown cystinuria. To illustrate
these important findings, we detail the genotype and phe-
notype of three families (Fig. 3).
Family ET
The propositus P7 (Fig. 3A, II-1) was diagnosed with
cystinuria after an antenatal hyperechogenic colon had
been identified through ultrasound during pregnancy. His
cystinuria was elevated (471 lmol/mmol creatinine) but
he never developed urinary stones up to the age of
5 years. The first mutated allele identified was
[A1 = c.163C>T; p.(Gln55*)], but no other second
SLC3A1 variant was found. We then sequenced the
SLC7A9 gene and identified a heterozygote variant
[B1 = c.544G>A; p.(Ala182Thr)] suggesting an AB geno-
type. Subsequently, QMPSF identified a second SLC3A1
mutated allele (A2 = c.(891+1_892-1)_(1617+1_1618-1)
dup) eventually proving genotype AAB. Interestingly, his
brother (II-2), 1 year older, has an A1B1 genotype and
has a normal cystine excretion (2 lmol/mmol creatinine).
Similarly, his father (I-1) bearing the A1B1 genotype is
asymptomatic but cystinuria data was unavailable. The
mother, heterozygote for A2, was also asymptomatic.
Family MA
A 25-year-old man, P21 (Fig. 3B, II-1) was diagnosed
with cystinuria after he passed a urinary stone. He was
born from nonconsanguineous parents who were both
asymptomatic. His genotype was at first thought to be
AO (A1 = c.647C>T; p.Thr216Met). We then sequenced
SLC7A9 and found one missense variant (B1 = c.26G>A;
p.Arg9Gln) which was predicted to be nondeleterious
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(Table S3). Subsequently, QMPSF analysis revealed a sec-
ond mutated allele in SLC3A1 (A2 = c.(765+1_766-1)_
(1011+1_1012-1)dup). Thus, his genotype was AA.
Family GA
The propositus P76 (Fig. 3C, III-1) is an 11-year-old girl
diagnosed with cystinuria after presenting with gross
hematuria. Direct sequencing identified a homozygous BB
genotype (B1 = c.614dup; pAsn206Glufs*3). Consanguin-
ity was not known in this family. The father (II-1) was
asymptomatic. The mother (II-2) did not suffer from uri-
nary stones but her cystinuria was, however, in the high
range (137 lmol/mmol creatinine). Besides the B1 allele,
we identified a SLC3A1 variant (A1 = c.566C>T;
pThr189Met) in the mother, giving her an AB genotype.
Of note, the grandmother (I-2) also suffered from typi-
cal cystine stone disease (diagnosed at the age of
16 years); unfortunately, her DNA was not available for
analysis.
In addition, large-scale rearrangement mapping enabled
us to comprehensively interpret two different genotypes
in affected siblings as described below.
Family CO
The propositus P70 (Fig. 3D, II-1) was diagnosed with
cystinuria after passing a renal stone at the age of
23 years. We identified a compound heterozygote SLC3A1
variants A1 = c.1500+1G>T and A2 = SLC3A1: c.(?_1)
_CAMKMT: c.(311+1_?)del. His sister (II-2) also had typ-
ical cystine stone disease diagnosed at the age of 18 years
(renal colic). Surprisingly, we did not identify the A2
allele but another A3 allele (c.1134C>A; pTyr378*). The
brother (II-3) was also affected and his genotype is A1/A3.
Furthermore, the father (I-1) had presented with cystine
stones but was deceased and DNA not available for study.
The mother (I-2) was asymptomatic and her cystinuria was
in the normal range (6 lmol/mmol). Her genotype was
A1/O. Thus, the genotype of the deceased father was most
certainly A2/A3.
Clinical characterization
A cohort of 112 patients from 99 families was character-
ized and a questionnaire addressing, age at first symp-
toms, stone recurrence rates, metabolic evaluations, and
follow-up was completed. Sufficient data were provided
for 109 patients belonging to 98 families (Table 4).
The male/female ratio was 58 (53.2%)/51 (46.8%).
Consanguinity was documented in 7/91 (7.7%) families.
Eight out of 109 patients did not develop any symptoms
due to their young age (the oldest being 8 years old) and/
or to preventive therapy. Median age at first clinical event
was 17 years (0 to 57) (mean 17  2) and 44/101
patients (43.6%) had less than 15 years at first symptoms.
For males, median age at first symptoms was 17 years (0
to 57) (mean age 15  3), whereas it was 17 years (2 to
40) (mean age 17  3) for females (P = 0.37). When
comparing according to genotype, median age at first
symptom was 17 years (0 to 57) (mean age 18  2) for
74 patients A and 12 years (1 to 40) (mean age 13  4)
for 22 patients B (P = 0.04). Median age at diagnosis of
cystinuria was 18 years (0 to 66) (mean age 20  3). It
was 21 years (0 to 66) (mean age 21  4) for males and
18 years (0 to 49) (mean age 20  3) for females.
Figure 2. Schematic representation of large-
scale rearrangements in SLC3A1, PREPL,
CAMKMT, and SLC7A9 genes. Genes are
written on top of the arrows indicating the
direction of the transcription. The exons are
indicated (squares). (A) Schematic
representation of 11 deletions in the 2p21
locus. (B) Schematic representation of 11
deletions in the SLC3A1 gene. (C) Schematic
representation of two deletions in the SLC7A9
gene.
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Urinary cystine excretion at the time of diagnosis for
89 patients was, in median 249 lmol/mmol creatinine
(65 to 958) (mean 285  37). It was 218 lmol/mmol
[72 to 896] (mean 245  44) in males and 290 lmol/
mmol [65 to 958] (mean 332  59) in females (P = 0.004).
Patients with genotype A had median cystinuria excre-
tion of 248 lmol/mmol [65 to 958] (mean 289  46),
whereas patients with genotype B had 264 lmol/mmol
(72 to 597) (mean 278  62) (P = 0.9).
Nephrolithiasis activity was assessed by the number of
urological interventions (spontaneous stone emission rate
was often lacking) related to the duration of the follow-
up, which was the period between the age at first sym-
ptoms and the age at the last follow-up. Concerning
surgical interventions, each patient had a median number
of 5 (0 to 26) (mean 7  1). During a median follow-up
of 18 years (1 to 59) (mean 22  3), median urological
intervention rate was 0.31/patient/year (0 to 2.67) (mean
0.46+/- 0.10). For males, it was 0.34/patient/year (0. to
2.67) (0.50  0.14) and for females, 0.29/patient/year (0 to
2.09) (mean 0.41  0.13) (P = 0.4). According to geno-
type, median intervention rates were 0.36/patient/year
(0 to 2.67) (mean 0.50  0.12) for patients A and 0.15/
patient/year (0 to 1.25) (mean 0.36  0.17) for patients B
(P = 0.1).
Among patients above 15 years of age, 19 patients
(21.8%) had chronic renal failure based on an eGFR
<60 mL/mn (estimated by the MDRD). Among them,
three patients had reached end stage renal failure at the
age of 22, 24, and 35 years.
Figure 3. Genealogic trees of four families.
(A) Family ET. A1 allele: c.163C>T –
p.(Gln55*); A2 allele= c.(891+1_892-1)_
(1617+1_1618-1)dup – p.(?); B1 allele=
c.544G>A – p.(Ala182Thr). (B) Family MA. A1
allele: c.647C>T – p.(Thr216Met); A2 allele:
c.(765+1_766-1)_(1011+1_1012-1)dup -
p.(Asp338Leufs*80); B1 allele: c.26G>A –
p.(Arg9Gln). This missense variant is not
predicted to be pathogenic (Table S3). (C)
Family GA. A1 allele: c.566C>T –
p.(Thr189Met); B1 allele: c.614dup –
p.(Asn206Glufs*3). (D) Family COL. A1 allele:
c.1500+1G>T – p.(?); A2 allele: SLC3A1;
NM_000341.3 :c.(?_1)_CAMKMT;
NM_024766.4 c.(311+1_?)del - p.(?); A3 allele:
c.1134C>A - p.(Tyr378*). A denotes SLC3A1
NM_000341; B denotes SLC7A9 NM_014270.
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In summary, 88 pathogenic variants have been identi-
fied; 153 and 46 mutated alleles have been reported in
SLC3A1 and SLC7A9 genes, respectively. Ninety-six
patients out of 99 were fully characterized at the molecu-
lar level, while in three subjects (P75, P98, P99) only one
mutated allele was identified in SLC7A9 or SLC3A1 genes.
It is worth noting that three mutated alleles have been
characterized in four patients (three patients with geno-
type AAA, one patient with genotype AAB). Indeed, this
study permits to classify the patients as follow: 74 patients
having a genotype A (70 AA, 3 AAA, 1 AAB), 22 with
genotype B, and 1 A0 and 2 B0 genotypes (Fig. 4). We
did not identify AB genotype among the affected patients.
Noticeably, two heterozygous variants in the SLC3A1 and
SLC7A9 genes (c.566C>T – p.(Thr189Met) and c.614dup
– p.(Asn206Glufs*3), respectively) were identified in a
nonsymptomatic mother. Her daughter (P76) presented
with cystinuria and a homozygous variant (c.614dup) was
characterized (Table S3).
Discussion
In this study, 112 cystinuric patients and 25 relatives from
99 families were screened for genomic variants of the
SLC3A1 and SLC7A9 genes. We identified 88 pathogenic
nucleotide changes of which 42 were novel. Recent studies
reported an equal distribution of genotype A and B in
European populations (Table S4). In our cohort, genotype
A is more frequent than genotype B (P < 0.0001); indeed,
74 patients out of 99 harbor genotype A (70 AA, 3 AAA,
1 AAB), while 22 patients have a genotype B. Only three
patients were not fully characterized (1A0 and 2 B0)
which allows us to reach a detection rate of 97% in our
cohort. Although disease variants are distributed
Table 4. Phenotype according to sex and genotype.
All (n = 109) Male (n = 58) Female (n = 51) AA (n = 81) BB (n = 24)
Age at first symptoms Number 97 52 45 73 20
Median 17 (0–57) 17 (0–57) 17 (2–40) 17 (0–57) 12 (1–40)*
Age at diagnosis Number 98 51 48 76 19
Median 18 (0–66) 21 (0–66) 18 (0–49) 21 (0–66) 14 (0–41)
Stone activity Number 96 52 44 72 20
Median 0.31 (0.00–2.67) 0.34 (0.00–2.67) 0.29 (0.00–2.09) 0.36 (0.00–2.67) 0.15 (0.00–1.25)
Follow-up Number 97 52 43 71 20
Median 18 (1–59) 21 (1–59) 18 (1–52) 17 (1–52) 22 (1–59)
Cystinuria (lmol/mmol creat) Number 89 48 41 65 21
Median 249 (65–958) 218 (72–896) 290 (65–958)** 248 (65–958) 264 (72–597)
Age at last follow-up Median 36 (2–86) 37 (2–86) 35 (3–83) 36 (3–86) 38 (2–67)
*P = 0.04 (BB vs. AA).
**P = 0.004 (Females vs. Males).
Figure 4. Genotype distribution of 99
patients. Seventy-four patients with genotype
A (70 AA, 3 AAA, 1 AAB), 22 with genotype
B, 1 A0 and 2 B0 genotypes.
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uniformly among regions within SLC3A1 and SLC7A9
genes, some of them are more common in specific popu-
lations (Chillaron et al. 2010). We compared the fre-
quency of common variants reported in a meta-analysis
(Chillaron et al. 2010) to that of our cohort (Table S5).
No significant difference was observed for p.(Thr216Met),
p.(Arg270*) variants in SLC3A1 gene and p.(Gly105Arg),
p.(Asn206Glufs*3), p.(Arg333Trp) variants in SLC7A9
gene. The missense p.(Met467Thr) and the duplication
c.(891+1_892-1)_(1617+1_1618-1)dup – p.(?) variants in
SLC3A1 gene are present with, respectively, a lower
(P = 0.01) and a higher (P = 0.002) prevalence in the
French cohort; the p.(Pro482Leu) variant in SLC7A9 gene
was not found in our cohort.
In an attempt to correlate genotypes and phenotypes,
we compared the disease activity in patients with two
missense variants (denoted as M), and patients with two
severe variants (large deletion, duplication, small deletion/
insertion, nonsense, splicing variants) denoted as S, in
either SLC3A1 or SLC7A9. Overall, 44 patients had M/M
genotype and 27 patients had an S/S genotype. No signi-
ficative differences were observed regarding age at first
symptoms, age at diagnosis, stone activity, and urinary
cystine excretion.
In this study, female patients have significantly higher
urinary excretion of cystine compared to male patients,
while no significant difference was observed in stone
activity rate. Interestingly, Dello Strologo et al. reported
that type B female patients had higher urinary excretion
of cystine while male patients had on average a higher
stone event rate than female patients (Dello Strologo
et al. 2002).
Six cases with an antenatally diagnosed hyperechogenic
colon were included in this study. No specific genotype
was associated to this very early manifestation of cystin-
uria. Indeed, the genotype was AA in 4/6 (P2, P6, P20,
P23), AAB in 1/6 (P7), and BB in 1/6 (P77). Only one
study reported molecular characterization of a case pre-
sented with hyperechogenic colon; a homozygous variant
in SLC3A1 gene (SLC3A1 NM_000341.3:c.833T>C –
p.(Phe278Ser) was identified (Buxmann et al. 2014). The
lack of genetic testing data impedes the correlation
between the prenatal finding and the corresponding geno-
type. To the best of our knowledge, this is the first report
of molecular characterization of a series of prenatal
cystinuria.
Importantly, this study shows how the experimental
assessment of the impact on splicing of SLC3A1 and
SLC7A9 variants contributed to the full molecular charac-
terization of cystinuria. Previously, in SLC3A1 and
SLC7A9 genes, a very limited number of variants have
been experimentally tested for their impact on splicing,
using RT-PCR analysis of patient RNA (Pras et al. 1998;
Font-Llitjos et al. 2005; Barbosa et al. 2011; Kummer
et al. 2014). Here, in addition to four variants located in
the most conserved positions of the splice sites (i.e., 2,
1/+1,+2), we identified using splicing minigene assays,
six new splicing mutations. These variants have been clas-
sified into two groups based on their effects. The first
group of splicing mutations alters directly the reference 50
splice sites resulting into total or partial exon skipping. It
includes two intronic variants and one synonymous vari-
ant located at the last base of the exon. The effects on
splice sites of these three variants were correctly predicted
by the in silico tool MaxEntSan. These data confirm the
good performance of this type of bioinformatics predic-
tion, as previously shown, in particular for large datasets
of BRCA1 and BRCA2 variants (Houdayer et al. 2012).
More surprisingly, the second group of splicing muta-
tions identified in this study induces exon skipping with-
out alteration of the splice sites. It included two
synonymous and one missense variants, located at dis-
tance from the splice sites. Their effects on splicing are
mediated through the potential modification of exonic
splicing regulatory elements (ESR). These 6–8 nucleotide
sequences correspond to binding sites for splicing activa-
tor (exonic splicing enhancer - ESE) or splicing repressor
proteins (exonic splicing silencer - ESS), respectively,
which modulate the recruitment and activity of the splic-
ing machinery. The three studied variants could either
destroy ESE and/or create ESS. Interestingly, two of the
splicing mutations, SLC7A9 c.120G>A - p.(=) and
c.209C>T - p.(Ala70Val), were identified in trans in a
patient (P96) and both induce exon 3 skipping. Of note,
the c.209C>T missense variant was supposed to induce a
very mild decrease in L-cystine transport activity (78% of
wild-type transport activity), as previously shown in func-
tional protein assay (Font et al. 2001). But, as for the syn-
onymous variant, we showed that this missense variant
would be pathogenic through an impact on splicing regu-
lation which would result onto a frameshift. To the best
of our knowledge, in the literature, there is only one vari-
ant in SLC7A9 gene reported to be responsible for a splic-
ing defect through the alteration of ESR (Kummer et al.
2014). Interestingly, this variant, c.225C>T - p.(=), is also
located in SLC7A9 exon 3, which suggest that the splicing
regulation of this exon might be particularly sensitive to
nucleotide changes. Based on this hypothesis, we per-
formed bioinformatics predictions that could apprehend
their effects on ESR. For this purpose, we used a recently
developed method based on the reported quantitative
evaluation of all RNA hexamers as potential ESR (Ke
et al. 2011), which allows the calculation of total ESRseq
score change (DtESRseq) for each variant, as previously
described (Di Giacomo et al. 2013; Soukarieh et al. 2016).
A good correlation has been previously described between
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the DtESRseq values and the experimental minigene data
obtained for two large sets of variants located either in
BRCA2 exon 7 (Di Giacomo et al. 2013) or in MLH1
exon 10 (Soukarieh et al. 2016). Interestingly, the three
SLC7A9 variants which experimentally induced exon 3
skipping are associated with negative DtESRseq values
(Table 3), predictive of ESE loss and/or ESS gain. These
data confirm the predictive power of this new in silico
approach for the detection of ESR mutations. Of note, in
the patient P97, two sequence variants were identified in
the SLC7A9 gene: one deleterious missense variant
c.1166C>T p.(Thr389Met) and one synonymous nucleo-
tide change, c.1032C>T p.(=), with unknown functional
effect. Our in silico analysis revealed that this variant is
associated with a negative DtESRseq value, predictive of a
perturbation on splicing regulation. Indeed, the splicing
minigene data confirmed that this variant induces the
complete skipping of exon 10 which would result into a
pathogenic frame shift. It would be of importance to con-
firm all these splicing defects from patient RNA but these
samples were not available.
Altogether, these results suggest that the number of
splicing mutations in SLC3A1 and SLC7A9 genes, espe-
cially those resulting into ESR alterations, might be cur-
rently underestimated. It has been estimated that
approximately one third of all disease-causing mutations
alter splicing (Lim et al. 2011). Today, in diagnostic
context, attention is given to intronic variants that
could directly disturb reference splice sites. Moreover,
special consideration should also be given to the poten-
tial splicing effects of exonic variants, whatever their
predicted consequences at the protein level (missense,
synonymous, or even nonsense). This study confirms
that bioinformatics approaches dedicated to splice sites
detection are useful for the identification of potential
splicing mutations and, more importantly, it also
extends the evaluation of a new in silico method based
on DtESRseq for the detection of potential ESR muta-
tions. This prediction method could represent a
promising tool for selecting potential ESR-alterating
splicing mutations among a large number of variants
before functional analysis. This strategy should improve
the molecular diagnosis of cystinuria by uncovering the
potential pathogenic nature of certain variants of
unknown significance (VUS), through the demonstra-
tion of their impact on splicing.
Besides, large-scale rearrangements play a significant
role in the etiology of the disease; large-scale deletions on
chromosome 2p21 may include SLC3A1, PERPL, and
CAMKMT genes. Moreover, duplications in SLC3A1 gene
and deletions in SLC7A9 gene were characterized. Thus,
QMPSF analyses allowed the detection of 37 mutated alle-
les (18% of mutant alleles).
The absence of AB genotype in recent studies and the
identification of an AB genotype in nonsymptomatic rela-
tives questioned the existence of the genotype AB
(Chatzikyriakidou et al. 2008; Bisceglia et al. 2010).
Indeed, no genotype AB has been identified in this study.
Although two heterozygous variants in SLC3A1 and
SLC7A9 genes, respectively, were characterized in two
cystinuric patients [P7 and P21 (Table S3)], QMPSF anal-
yses of SLC3A1 gene allowed the identification of large
duplications enabling to classify them as genotype A. In
addition, genotype AB was identified in two nonsymp-
tomatic relatives from two different families. These find-
ings strongly support that digenic inheritance is unlikely.
Besides, considering the high frequency of large-scale
deletion SLC3A1 gene, we decided to perform QMPSF
analysis in the 17 patients for whom a homozygous mis-
sense/nonsense variant was identified. Indeed, in three
patients, P30, P33, and P39, QMPSF analysis allowed the
identification of a deletion of the same region in which
the missense/nonsense variant is located.
A part of negative genetic testing of cystinuria could be
due to large genomic rearrangements that are missed by
direct sequencing. Of note, two patients presented with
Hypotonia-Cystinuria Syndrome - HCS (P31 and P72,
Table S3) and suffered from neonatal hypotonia, growth
retardation in addition to cystinuria. As in all HCS cases,
our patients were homozygous for large-scale 2p21 dele-
tions. These variants involved both SLC3A1 and the
neighbored gene PREPL [SLC3A1 NM_000341.3:
c.(430+1_431-1)_PREPL NM_006036.4:c.(219+1_?)del and
SLC3A1 NM_000341.3:c.(?_892-1)_PREPL; NM_006036.4:
c.(1896+1_?)del] in P31 and P72, respectively.
The breakpoints of these large-scale variants may corre-
spond to a high frequency of repetitive sequences within
the SLC3A1, PREPL, and CAMKMT genes. Regions with
high repeat sequence content are prone to nonallelic
homologous recombination. RepeatMasker analysis
showed that SLC3A1, PREPL, and CAMKMT genes con-
tain a total of interspersed repeats in intronic regions cor-
responding, respectively, to 51.4%, 38%, and 46.5% of
the gene sequence (Tarailo-Graovac and Chen 2009).
Indeed, Bisceglia et al. reported that the breakpoint of
exons 2-4 deletion involves Alu repeats at 227 bp
upstream of exon 2 and 11680 bp downstream of exon 4
(c.431-227_891+11680del17349) (Bisceglia et al. 2010).
Besides, Schmidt et al. proposed that the duplication of
exon 5 to exon 9 might be mediated by an unequal cross-
ing-over between intron 9 and intron 4 homologous
regions (Schmidt et al. 2003).
In conclusion, this is the first study that investigated
the molecular basis of cystinuria in French patients and
the present report highlights that systematic screening for
large-scale rearrangements and specific investigations for
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the detection of splicing mutations are critical for the
molecular characterization of cystinuria.
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